BioCentury
ARTICLE | Finance

Deep pockets

Why Deciphera thinks the time was right to tap VC money

September 28, 2015 7:00 AM UTC

With four unpartnered cancer compounds in or entering the clinic, Deciphera Pharmaceuticals LLC decided it was finally time to raise venture money. Last week's $75 million series B round from a syndicate led by New Leaf Venture Partners should give the biotech enough runway to get to multiple data events.

"They've been successful moving molecules forward, and that causes capital needs to rise significantly. It was time to bring in others," said New Leaf's Liam Ratcliffe, who joined the board. ...